Investors need to pay close attention to Aditx (ADTX) stock based on the movements in the options market lately.
RICHMOND, Va., January 03, 2023--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based subsidiary Adimune, Inc. ("Adimune™) and its plans towards submission of a Clinical Trial Application ("CTA") for its immunotherapeutic technology drug candidate, ADI™-100 ("ADI™-100" or "ADI™"). The CTA application will request a
Investors need to pay close attention to Aditx Therapeutics (ADTX) stock based on the movements in the options market lately.